本帖最后由 老马 于 2013-3-13 13:43 编辑 / q R' {3 S1 P9 ]
; l5 K: a* ?; f7 d# k
健择(吉西他滨)+顺铂+阿瓦斯汀3 j5 [. I& l$ l- s3 L
Gemzar +Cisplatin + Avastin7 M# G# q2 |1 D2 k5 {2 ^
http://annonc.oxfordjournals.org/content/21/9/1804.full, y! V' O) _) p2 V- d3 x7 a' d
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 2 {! g# A, d$ v# l; n! G3 c
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
. S3 T- ]7 N' k8 [/ c {0 tResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ) q2 G% w9 s( ^9 U6 ^
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 759)
$ P2 E8 @% q2 Q' L I2 b" z华为网盘附件:
, ~3 ^4 Y' Q z8 x7 r% u3 |8 ]6 Y【华为网盘】ava.JPG& v& }% h! I8 E6 p6 y; m2 l
|